ERAS
Erasca, Inc.
$14.12
-0.18
(-1.26%)
Mkt Cap
4.90B
Volume
3,834,689
52W Range
2.105-24.28
Sector
Healthcare
Beta
0.62
EPS (TTM)
-0.95 USD
P/E Ratio
-8.45
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (124.55M) | (161.65M) | (125.04M) | (242.81M) | (122.76M) | (101.66M) | (12.04M) |
| EPS | -0.44 | -0.69 | -0.83 | -1.99 | -1.03 | -0.85 | -0.10 |
| Free Cash Flow | (95.58M) | (131.98M) | (102.99M) | (119.81M) | (98.48M) | (71.38M) | (10.97M) |
| FCF / Share | -0.34 | -0.56 | -0.69 | -0.98 | -0.83 | -0.60 | -0.09 |
| Operating CF | (95.45M) | (109.42M) | (101.22M) | (103.26M) | (79.60M) | (32.69M) | (10.38M) |
| Total Assets | 396.15M | 502.53M | 395.30M | 514.91M | 501.42M | 124.83M | 55.51M |
| Total Debt | 47.14M | 51.89M | 55.86M | 55.10M | 18.79M | 2.99M | 3.69M |
| Cash & Equiv | 73.81M | 67.74M | 93.08M | 284.22M | 360.49M | 65.38M | 29.58M |
| Book Value | 325.17M | 423.50M | 316.69M | 411.85M | 456.53M | 107.42M | (13.60M) |
| Return on Equity | -0.38 | -0.38 | -0.39 | -0.59 | -0.27 | -0.95 | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (44.08M) | (183.44M) | (29.09M) | (30.61M) | (33.88M) | (30.97M) | (32.23M) | (31.20M) | (63.20M) | (35.02M) | (29.70M) | (30.36M) |
| EPS | -0.14 | -0.60 | -0.10 | -0.11 | -0.12 | -0.11 | -0.11 | -0.11 | -0.29 | -0.23 | -0.20 | -0.20 |
| Free Cash Flow | (27.28M) | (27.42M) | (21.72M) | (21.66M) | (20.56M) | (31.64M) | (24.56M) | (22.42M) | (29.20M) | (33.29M) | (24.87M) | (24.36M) |
| FCF / Share | -0.09 | -0.09 | -0.08 | -0.08 | -0.07 | -0.11 | -0.09 | -0.08 | -0.13 | -0.22 | -0.16 | -0.16 |
| Operating CF | (27.27M) | (27.38M) | (21.71M) | (21.66M) | (20.53M) | (31.55M) | (24.56M) | (22.42M) | (29.18M) | (33.25M) | (24.79M) | (24.12M) |
| Total Assets | 435.05M | 461.23M | 396.15M | 420.40M | 445.39M | 471.24M | 502.53M | 528.90M | 525.74M | 370.02M | 395.30M | 419.41M |
| Total Debt | 44.71M | 45.95M | 47.14M | 48.29M | 49.42M | 50.81M | 51.89M | 52.94M | 53.97M | 65.97M | 55.86M | 56.76M |
| Cash & Equiv | 42.54M | 47.26M | 73.81M | 70.23M | 66.14M | 70.48M | 67.74M | 68.89M | 172.80M | 76.73M | 93.08M | 112.86M |
| Book Value | 361.87M | 393.53M | 325.17M | 347.89M | 372.26M | 399.50M | 423.50M | 450.04M | 451.09M | 288.41M | 316.69M | 338.98M |
| Return on Equity | -0.12 | -0.47 | -0.09 | -0.09 | -0.09 | -0.08 | -0.08 | -0.07 | -0.14 | -0.12 | -0.09 | -0.09 |
ERAS News
Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower
Erasca, Inc. (NASDAQ:ERAS) Stock Has Consensus Target Price of $22.09
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims
Engineers Gate Manager LP Takes Position in Erasca, Inc. $ERAS
Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium